For research use only. Not for therapeutic Use.
Cabozantinib(Cat No.:A000716)is a potent multi-kinase inhibitor that targets several receptors, including MET, VEGFR, AXL, and RET, which are involved in tumor growth, angiogenesis, and metastasis. By inhibiting these pathways, cabozantinib disrupts cancer cell proliferation and the formation of new blood vessels that supply tumors. It is primarily used in the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Cabozantinib’s broad activity against multiple signaling pathways makes it a crucial agent in cancer research and targeted therapy development, particularly for aggressive and treatment-resistant cancers.
Catalog Number | A000716 |
CAS Number | 849217-68-1 |
Synonyms | XL184, BMS-907351; |
Molecular Formula | C₂₈H₂₄FN₃O₅ |
Purity | ≥95% |
Target | Apoptosis |
Solubility | >25.1mg/mL in DMSO |
Storage | <label class= |
Overview of Clinical Research | Originator: Exelixis<br /> |
IUPAC Name | 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
InChI | InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34) |
InChIKey | ONIQOQHATWINJY-UHFFFAOYSA-N |
SMILES | COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F |
Reference | 1: Roy S, Narang BK, Rastogi SK, Rawal RK. A novel multiple tyrosine-kinase <br> <br> <br> 5: Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary |